Home  »  Companies   »  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Has Out...

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Has Outstanding Potential

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares, rose in value on Thursday, 06/23/22, with the stock price up by 27.90% to the previous day’s close as strong demand from buyers drove the stock to $5.41.

Actively observing the price movement in the last trading, the stock closed the session at $4.23, falling within a range of $4.335 and $5.42. Referring to stock’s 52-week performance, its high was $31.54, and the low was $3.59. On the whole, ORMP has fluctuated by 17.86% over the past month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Analysts have estimated the company’s revenue for the quarter at $2.77 million, with a low estimate of $2.7 million and a high estimate of $2.8 million.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ORMP’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

4 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 4 recommend it as a Buy and 0 called the ORMP stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ORMP currently trading nearly 22.68% and 7.42% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.25, while the 7-day volatility ratio is showing 12.46% which for the 30-day chart, stands at 9.22%. Furthermore, Oramed Pharmaceuticals Inc. (ORMP)’s beta value is 1.99, and its average true range (ATR) is 0.45. The company’s stock has been forecasted to trade at an average price of $28.00 over the course of the next 52 weeks, with a low of $20.00 and a high of $32.00. Based on these price targets, the low is -269.69% off current price, whereas the price has to move -491.5% to reach the yearly target high. Additionally, analysts’ median price of $30.00 is likely to be welcomed by investors because it represents a decrease of -454.53% from the current levels.

A comparison of Oramed Pharmaceuticals Inc. (ORMP) with its peers suggests the former has fared considerably weaker in the market. ORMP showed an intraday change of 27.90% in last session, and over the past year, it shrunk by -61.58%%. In comparison, Sanofi (SNY) has moved higher at 0.38% on the day and was down -2.67% over the past 12 months. On the other hand, the price of Novo Nordisk A/S (NVO) has risen 1.02% on the day. The stock, however, is off 32.80% from where it was a year ago. Additionally, there is a gain of 6.90% for Ultragenyx Pharmaceutical Inc. (RARE) in last trading while the stock has seen an overall depriciation of -35.99%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.95%. Meanwhile, the Dow Jones Industrial Improved by 0.64%.

Data on historical trading for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) indicates that the trading volumes over the past 3 months, they’ve averaged 704.95K. According to company’s latest data on outstanding shares, there are 38.68 million shares outstanding.

Nearly 3.90% of Oramed Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 27.00% of the company’s shares. The stock has fallen by -62.11% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ORMP stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts